{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:16:50Z","timestamp":1778933810789,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40256-021-00472-y","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T04:15:48Z","timestamp":1616386548000},"page":"609-617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medical Therapies for Marfan Syndrome and Other Thoracic Aortic Dilatation in Adults: A Contemporary Review"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-0235","authenticated-orcid":false,"given":"Duygu","family":"Kocyigit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian P.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-7468","authenticated-orcid":false,"given":"Bo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"472_CR1","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.jacc.2010.02.015","volume":"55","author":"LF Hiratzka","year":"2010","unstructured":"Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, et al. 2010 ACCF\/AHA\/AATS\/ACR\/ASA\/SCA\/SCAI\/SIR\/STS\/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. J Am Coll Cardiol. 2010;55:e27\u2013129. https:\/\/doi.org\/10.1016\/j.jacc.2010.02.015.","journal-title":"J Am Coll Cardiol."},{"key":"472_CR2","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1161\/CIRCULATIONAHA.116.022995","volume":"134","author":"A Masri","year":"2016","unstructured":"Masri A, Kalahasti V, Svensson LG, Roselli EE, Johnston D, Hammer D, et al. Aortic cross-sectional area\/height ratio and outcomes in patients with a trileaflet aortic valve and a dilated aorta. Circulation. 2016;134:1724\u201337. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.022995.","journal-title":"Circulation"},{"key":"472_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.echo.2019.11.008","volume":"33","author":"B Xu","year":"2020","unstructured":"Xu B, Kocyigit D, Betancor J, Tan C, Rodriguez ER, Schoenhagen P, et al. Sinus of valsalva aneurysms: a state-of-the-art imaging review. J Am Soc Echocardiogr. 2020;33:295\u2013312. https:\/\/doi.org\/10.1016\/j.echo.2019.11.008.","journal-title":"J Am Soc Echocardiogr."},{"key":"472_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1161\/01.CIR.0000154569.08857.7A","volume":"111","author":"EM Isselbacher","year":"2005","unstructured":"Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation. 2005;111:816\u201328. https:\/\/doi.org\/10.1161\/01.CIR.0000154569.08857.7A.","journal-title":"Circulation"},{"key":"472_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1161\/CIRCRESAHA.118.312436","volume":"124","author":"A Pinard","year":"2019","unstructured":"Pinard A, Jones GT, Milewicz DM. Genetics of thoracic and abdominal aortic diseases. Circ Res. 2019;124:588\u2013606. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.312436.","journal-title":"Circ Res."},{"key":"472_CR6","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1093\/eurheartj\/ehu281","volume":"35","author":"R Erbel","year":"2014","unstructured":"Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2873\u2013926. https:\/\/doi.org\/10.1093\/eurheartj\/ehu281.","journal-title":"Eur Heart J."},{"issue":"6","key":"472_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/eurheartj\/ehaa554","volume":"42","author":"H Baumgartner","year":"2021","unstructured":"Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563\u2013645. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa554.","journal-title":"Eur Heart J."},{"key":"472_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0006-2952(83)90555-5","volume":"32","author":"RJ Boucek","year":"1983","unstructured":"Boucek RJ, Gunja-Smith Z, Noble NL, Simpson CF. Modulation by propranolol of the lysyl cross-links in aortic elastin and collagen of the aneurysm-prone turkey. Biochem Pharmacol. 1983;32:275\u201380.","journal-title":"Biochem Pharmacol."},{"key":"472_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/0741-5214(94)90004-3","volume":"20","author":"JM Slaiby","year":"1994","unstructured":"Slaiby JM, Ricci MA, Gadowski GR, Hendley ED, Pilcher DB. Expansion of aortic aneurysms is reduced by propranolol in a hypertensive rat model. J Vasc Surg. 1994;20:178\u201383. https:\/\/doi.org\/10.1016\/0741-5214(94)90004-3.","journal-title":"J Vasc Surg."},{"key":"472_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1056\/NEJM199405123301902","volume":"330","author":"J Shores","year":"1994","unstructured":"Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan\u2019s syndrome. N Engl J Med. 1994;330:1335\u201341. https:\/\/doi.org\/10.1056\/NEJM199405123301902.","journal-title":"N Engl J Med."},{"key":"472_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/0002-9149(94)90762-5","volume":"74","author":"MA Salim","year":"1994","unstructured":"Salim MA, Alpert BS, Ward JC, Pyeritz RE. Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol. 1994;74:629\u201333. https:\/\/doi.org\/10.1016\/0002-9149(94)90762-5.","journal-title":"Am J Cardiol."},{"key":"472_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.amjcard.2006.08.048","volume":"99","author":"M Ladouceur","year":"2007","unstructured":"Ladouceur M, Fermanian C, Lupoglazoff JM, Edouard T, Dulac Y, Acar P, et al. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol. 2007;99:406\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2006.08.048.","journal-title":"Am J Cardiol."},{"key":"472_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s0002-9149(00)80066-1","volume":"75","author":"DI Silverman","year":"1995","unstructured":"Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, et al. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75:157\u201360. https:\/\/doi.org\/10.1016\/s0002-9149(00)80066-1.","journal-title":"Am J Cardiol."},{"key":"472_CR14","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127\u2013248. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.006.","journal-title":"J Am Coll Cardiol."},{"key":"472_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/heart.87.4.395","volume":"87","author":"NA Boon","year":"2002","unstructured":"Boon NA, Bloomfield P. The medical management of valvar heart disease. Heart. 2002;87:395\u2013400. https:\/\/doi.org\/10.1136\/heart.87.4.395.","journal-title":"Heart"},{"key":"472_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jacc.2009.02.077","volume":"54","author":"U Sampat","year":"2009","unstructured":"Sampat U, Varadarajan P, Turk R, Kamath A, Khandhar S, Pai RG. Effect of beta-blocker therapy on survival in patients with severe aortic regurgitation results from a cohort of 756 patients. J Am Coll Cardiol. 2009;54:452\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.077.","journal-title":"J Am Coll Cardiol."},{"key":"472_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1126\/science.1192152","volume":"332","author":"JP Habashi","year":"2011","unstructured":"Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011;332:361\u20135. https:\/\/doi.org\/10.1126\/science.1192152.","journal-title":"Science"},{"key":"472_CR18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1365-2362.2012.02668.x","volume":"42","author":"A Williams","year":"2012","unstructured":"Williams A, Kenny D, Wilson D, Fagenello G, Nelson M, Dunstan F, et al. Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome: a randomised, double-blind, crossover trial. Eur J Clin Invest. 2012;42:891\u20139. https:\/\/doi.org\/10.1111\/j.1365-2362.2012.02668.x.","journal-title":"Eur J Clin Invest."},{"key":"472_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1126\/science.1124287","volume":"312","author":"JP Habashi","year":"2006","unstructured":"Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117\u201321. https:\/\/doi.org\/10.1126\/science.1124287.","journal-title":"Science"},{"key":"472_CR20","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","volume":"34","author":"M Groenink","year":"2013","unstructured":"Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;34:3491\u2013500. https:\/\/doi.org\/10.1093\/eurheartj\/eht334.","journal-title":"Eur Heart J."},{"key":"472_CR21","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1093\/eurheartj\/ehaa377","volume":"41","author":"MM van Andel","year":"2020","unstructured":"van Andel MM, Indrakusuma R, Jalalzadeh H, Balm R, Timmermans J, Scholte AJ, et al. Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial. Eur Heart J. 2020;41:4181\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa377.","journal-title":"Eur Heart J."},{"key":"472_CR22","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1093\/eurheartj\/ehv151","volume":"36","author":"O Milleron","year":"2015","unstructured":"Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015;36:2160\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehv151.","journal-title":"Eur Heart J."},{"key":"472_CR23","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/00015385.2017.1314134","volume":"72","author":"L Muino-Mosquera","year":"2017","unstructured":"Muino-Mosquera L, De Nobele S, Devos D, Campens L, De Paepe A, De Backer J. Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial. Acta Cardiol. 2017;72:616\u201324. https:\/\/doi.org\/10.1080\/00015385.2017.1314134.","journal-title":"Acta Cardiol."},{"key":"472_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.mayocp.2012.11.005","volume":"88","author":"HH Chiu","year":"2013","unstructured":"Chiu HH, Wu MH, Wang JK, Lu CW, Chiu SN, Chen CA, et al. Losartan added to beta-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc. 2013;88:271\u20136. https:\/\/doi.org\/10.1016\/j.mayocp.2012.11.005.","journal-title":"Mayo Clin Proc."},{"key":"472_CR25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/eurheartj\/ehv575","volume":"37","author":"A Forteza","year":"2016","unstructured":"Forteza A, Evangelista A, Sanchez V, Teixido-Tura G, Sanz P, Gutierrez L, et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. Eur Heart J. 2016;37:978\u201385. https:\/\/doi.org\/10.1093\/eurheartj\/ehv575.","journal-title":"Eur Heart J."},{"key":"472_CR26","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jacc.2018.07.052","volume":"72","author":"G Teixido-Tura","year":"2018","unstructured":"Teixido-Tura G, Forteza A, Rodriguez-Palomares J, Gonzalez Mirelis J, Gutierrez L, Sanchez V, et al. Losartan versus atenolol for prevention of aortic dilation in patients with Marfan syndrome. J Am Coll Cardiol. 2018;72:1613\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2018.07.052.","journal-title":"J Am Coll Cardiol."},{"key":"472_CR27","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","volume":"371","author":"RV Lacro","year":"2014","unstructured":"Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, et al. Atenolol versus losartan in children and young adults with Marfan\u2019s syndrome. N Engl J Med. 2014;371:2061\u201371. https:\/\/doi.org\/10.1056\/NEJMoa1404731.","journal-title":"N Engl J Med."},{"key":"472_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/1358863X15569868","volume":"20","author":"AB Bhatt","year":"2015","unstructured":"Bhatt AB, Buck JS, Zuflacht JP, Milian J, Kadivar S, Gauvreau K, et al. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vasc Med. 2015;20:317\u201325. https:\/\/doi.org\/10.1177\/1358863X15569868.","journal-title":"Vasc Med."},{"key":"472_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1161\/CIRCGENETICS.114.000950","volume":"8","author":"R Franken","year":"2015","unstructured":"Franken R, den Hartog AW, Radonic T, Micha D, Maugeri A, van Dijk FS, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Genet. 2015;8:383\u20138. https:\/\/doi.org\/10.1161\/CIRCGENETICS.114.000950.","journal-title":"Circ Cardiovasc Genet."},{"key":"472_CR30","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/S0140-6736(19)32518-8","volume":"394","author":"M Mullen","year":"2020","unstructured":"Mullen M, Jin XY, Child A, Stuart AG, Dodd M, Aragon-Martin JA, et al. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet. 2020;394:2263\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(19)32518-8.","journal-title":"Lancet"},{"key":"472_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s0895-7061(97)00491-3","volume":"11","author":"K Kassler-Taub","year":"1998","unstructured":"Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan\/Losartan Study Investigators. Am J Hypertens. 1998;11:445\u201353. https:\/\/doi.org\/10.1016\/s0895-7061(97)00491-3.","journal-title":"Am J Hypertens."},{"key":"472_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.amjcard.2020.04.034","volume":"128","author":"A Al-Abcha","year":"2020","unstructured":"Al-Abcha A, Saleh Y, Mujer M, Boumegouas M, Herzallah K, Charles L, et al. Meta-analysis examining the usefulness of angiotensin receptor blockers for the prevention of aortic root dilation in patients with the Marfan syndrome. Am J Cardiol. 2020;128:101\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2020.04.034.","journal-title":"Am J Cardiol."},{"key":"472_CR33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.amjcard.2011.11.038","volume":"109","author":"IS Jovin","year":"2012","unstructured":"Jovin IS, Duggal M, Ebisu K, Paek H, Oprea AD, Tranquilli M, et al. Comparison of the effect on long-term outcomes in patients with thoracic aortic aneurysms of taking versus not taking a statin drug. Am J Cardiol. 2012;109:1050\u20134. https:\/\/doi.org\/10.1016\/j.amjcard.2011.11.038.","journal-title":"Am J Cardiol."},{"key":"472_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijcard.2015.05.001","volume":"191","author":"E Angeloni","year":"2015","unstructured":"Angeloni E, Vitaterna A, Pirelli M, Refice S. Effects of statin therapy on ascending aorta aneurysms growth: a propensity-matched analysis. Int J Cardiol. 2015;191:52\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.001.","journal-title":"Int J Cardiol."},{"key":"472_CR35","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/s0828-282x(07)70883-8","volume":"23","author":"S Singh","year":"2007","unstructured":"Singh S, Trivedi A, Adhikari T, Molnar J, Arora R, Khosla S. Cocaine-related acute aortic dissection: patient demographics and clinical outcomes. Can J Cardiol. 2007;23:1131\u20134. https:\/\/doi.org\/10.1016\/s0828-282x(07)70883-8.","journal-title":"Can J Cardiol."},{"key":"472_CR36","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.amjmed.2014.05.005","volume":"127","author":"JH Dean","year":"2014","unstructured":"Dean JH, Woznicki EM, O\u2019Gara P, Montgomery DG, Trimarchi S, Myrmel T, et al. Cocaine-related aortic dissection: lessons from the International Registry of Acute Aortic Dissection. Am J Med. 2014;127:878\u201385. https:\/\/doi.org\/10.1016\/j.amjmed.2014.05.005.","journal-title":"Am J Med."},{"key":"472_CR37","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1540-8191.2007.00432.x","volume":"22","author":"E Wako","year":"2007","unstructured":"Wako E, LeDoux D, Mitsumori L, Aldea GS. The emerging epidemic of methamphetamine-induced aortic dissections. J Card Surg. 2007;22:390\u20133. https:\/\/doi.org\/10.1111\/j.1540-8191.2007.00432.x.","journal-title":"J Card Surg."},{"key":"472_CR38","doi-asserted-by":"publisher","first-page":"e010077","DOI":"10.1136\/bmjopen-2015-010077","volume":"5","author":"N Daneman","year":"2015","unstructured":"Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015;5:e010077. https:\/\/doi.org\/10.1136\/bmjopen-2015-010077.","journal-title":"BMJ Open."},{"key":"472_CR39","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1001\/jamainternmed.2015.5389","volume":"175","author":"CC Lee","year":"2015","unstructured":"Lee CC, Lee MT, Chen YS, Lee SH, Chen YS, Chen SC, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175:1839\u201347. https:\/\/doi.org\/10.1001\/jamainternmed.2015.5389.","journal-title":"JAMA Intern Med."},{"key":"472_CR40","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jacc.2018.06.067","volume":"72","author":"CC Lee","year":"2018","unstructured":"Lee CC, Lee MG, Hsieh R, Porta L, Lee WC, Lee SH, et al. Oral fluoroquinolone and the risk of aortic dissection. J Am Coll Cardiol. 2018;72:1369\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.067.","journal-title":"J Am Coll Cardiol."},{"key":"472_CR41","doi-asserted-by":"publisher","first-page":"k678","DOI":"10.1136\/bmj.k678","volume":"360","author":"B Pasternak","year":"2018","unstructured":"Pasternak B, Inghammar M, Svanstrom H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678. https:\/\/doi.org\/10.1136\/bmj.k678.","journal-title":"BMJ"},{"key":"472_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1871525717666190402121958","volume":"17","author":"P Rawla","year":"2019","unstructured":"Rawla P, El Helou ML, Vellipuram AR. Fluoroquinolones and the risk of aortic aneurysm or aortic dissection: a systematic review and meta-analysis. Cardiovasc Hematol Agents Med Chem. 2019;17:3\u201310. https:\/\/doi.org\/10.2174\/1871525717666190402121958.","journal-title":"Cardiovasc Hematol Agents Med Chem."},{"key":"472_CR43","doi-asserted-by":"publisher","first-page":"e181804","DOI":"10.1001\/jamasurg.2018.1804","volume":"153","author":"SA LeMaire","year":"2018","unstructured":"LeMaire SA, Zhang L, Luo W, Ren P, Azares AR, Wang Y, et al. Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice. JAMA Surg. 2018;153:e181804. https:\/\/doi.org\/10.1001\/jamasurg.2018.1804.","journal-title":"JAMA Surg."},{"key":"472_CR44","unstructured":"US FDA. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. FDA Drug Safety Communication. 2018. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics. Accessed 8 Apr 2020."},{"key":"472_CR45","unstructured":"European Medicines Agency. Systemic and inhaled fluoroquinolones: risk of heart valve regurgitation\/incompetence. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/systemic-inhaled-fluoroquinolones-risk-heart-valve-regurgitationincompetence. Accessed 14 Dec 2020."},{"key":"472_CR46","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.4192","author":"YH Dong","year":"2020","unstructured":"Dong YH, Chang CH, Wang JL, Wu LC, Lin JW, Toh S. Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med. 2020. https:\/\/doi.org\/10.1001\/jamainternmed.2020.4192.","journal-title":"JAMA Intern Med."},{"key":"472_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.4199","author":"C Gopalakrishnan","year":"2020","unstructured":"Gopalakrishnan C, Bykov K, Fischer MA, Connolly JG, Gagne JJ, Fralick M. Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med. 2020. https:\/\/doi.org\/10.1001\/jamainternmed.2020.4199.","journal-title":"JAMA Intern Med."},{"key":"472_CR48","doi-asserted-by":"publisher","first-page":"e08648","DOI":"10.7554\/eLife.08648","volume":"4","author":"JJ Doyle","year":"2015","unstructured":"Doyle JJ, Doyle AJ, Wilson NK, Habashi JP, Bedja D, Whitworth RE, et al. A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. Elife. 2015;4:e08648. https:\/\/doi.org\/10.7554\/eLife.08648.","journal-title":"Elife."},{"key":"472_CR49","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J."},{"key":"472_CR50","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.jtcvs.2018.02.115","volume":"156","author":"MA Borger","year":"2018","unstructured":"Borger MA, Fedak PWM, Stephens EH, Gleason TG, Girdauskas E, Ikonomidis JS, et al. The American Association for Thoracic Surgery consensus guidelines on bicuspid aortic valve-related aortopathy: full online-only version. J Thorac Cardiovasc Surg. 2018;156:e41\u201374. https:\/\/doi.org\/10.1016\/j.jtcvs.2018.02.115.","journal-title":"J Thorac Cardiovasc Surg."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00472-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-021-00472-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00472-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T03:14:03Z","timestamp":1636341243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-021-00472-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["472"],"URL":"https:\/\/doi.org\/10.1007\/s40256-021-00472-y","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"19 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to assist in the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Duygu Kocyigit, Brian P. Griffin, and Bo Xu declare they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"All authors contributed to the study conception. The literature search was performed by DK, who also wrote the first draft of the manuscript. BPG and BX commented on subsequent versions of the manuscript, and all authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}